However, Zhang et al. revealed that the anti-tumor activity of afatinib on intrahepatic cholangiocarcinoma was due to silencing of the EGFR/STAT3 signaling pathway [48]. The gene discussed is EGFR; the disease is intrahepatic cholangiocarcinoma.